(Q48224963)

English

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains

scientific article published in March 1999

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Bengt Långström

8

object named as

Långström B

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

author name string

Ekesbo A

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Torstenson R

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Hartvig P

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Carlsson A

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Sonesson C

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Waters N

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Tedroff J

7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

publication date

1 March 1999

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Neuropharmacology

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

38

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

331-338

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Parkinson's disease: pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Dopamine-induced recruitment of dopamine D1 receptors to the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

A preliminary evaluation of the Scanditronix PC2048-15B brain scanner

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

SCH 23390—The first selective dopamine D-1 antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Long-term effects of tetrabenazine in hyperkinetic movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

An increase in the in vivo binding of [3H]SCH 23390 induced by MK-801 in the mouse striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Performance characteristics of an eight-ring whole body PET scanner

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Receptor basis for dopaminergic supersensitivity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Antiparkinsonian actions of glutamate antagonists--alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2898%2900200-7

7 January 2021

Identifiers

10.1016/S0028-3908(98)00200-7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/10219971

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48224963&oldid=2190977494"